Moderna (MRNA) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 605.6% versus a gain of 31.2%. Over five years, REGN leads with a +33.7% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($78.65 billion vs $76.14 billion), about 1.0 times the size, while Regeneron Pharmaceuticals is growing revenue faster (+1.0% vs -39.9%).
Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Moderna does not currently pay one. Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | REGN |
|---|---|---|
| Share price | $197.00 | $739.57 |
| Market cap | $78.65B | $76.14B |
| 1-day change | +0.26% | -0.34% |
| YTD return | +568.02% | -4.18% |
| 1-year return | +605.59% | +31.16% |
| 5-year return | -39.24% | +33.68% |
| P/E ratio (TTM) | — | 18.29 |
| Forward P/E | — | 11.99 |
| EPS (TTM) | $-7.98 | $40.44 |
| Dividend yield | 0.00% | 0.49% |
| Annual dividend | $0.00 | $3.64 |
| Revenue (latest FY) | $1.94B | $14.34B |
| Revenue growth (YoY) | -39.93% | +0.99% |
| Net income (latest FY) | $-2.82B | $4.50B |
| Gross margin | 55.35% | — |
| Operating margin | -158.13% | 24.95% |
| Net margin | -145.16% | 31.41% |
| 52-week high | $212.22 | $859.34 |
| 52-week low | $22.28 | $541.00 |
| Distance from 52-week high | -7.17% | -13.94% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -38.58% | +15.77% |
| Average volume | 17.44M | 736.98K |
| Shares outstanding | 399.24M | 101.14M |
| Employees | 4,700 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRNA has outperformed REGN by 574.4 percentage points over the past year.
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Regeneron Pharmaceuticals grew revenue faster in its latest fiscal year (+0.99% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
MRNA vs REGN FAQ
Which is bigger, Moderna or Regeneron Pharmaceuticals?
Moderna (MRNA) is larger, with a market capitalization of $78.65B compared with $76.14B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, MRNA or REGN?
MRNA returned +605.59% over the past 12 months, compared with +31.16% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Moderna or Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals pays a dividend yielding 0.49%, while Moderna does not currently pay a regular dividend.
Are Moderna and Regeneron Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Moderna and Biotechnology: Pharmaceutical Preparations for Regeneron Pharmaceuticals.